Merck Down Nearly 5%, on Pace for Largest Percent Decrease Since October 2017 -- Data Talk
10 September 2019 - 4:46PM
Dow Jones News
Merck & Co., Inc. (MRK) is currently at $79.32, down $4.15
or 4.97%
-- Would be lowest close since May 31, 2019, when it closed at
$79.21
-- On pace for largest percent decrease since Oct. 30, 2017,
when it fell 6.06%
-- Merck (NYSE: MRK), known as MSD outside the United States and
Canada, today announced that first-line treatment with KEYTRUDA,
Merck's anti-PD-1 therapy, in combination with chemotherapy
demonstrated improvements in overall survival (OS),
progression-free survival (PFS) and objective response rate (ORR)
in a pooled analysis of a subgroup of patients with advanced
nonsquamous and squamous non-small cell lung cancer (NSCLC) whose
tumors do not express PD-L1 (tumor proportion score [TPS] <1%)
from three randomized trials
-- Down 8.27% month-to-date
-- Up 3.81% year-to-date
-- Down 11.67% from its all-time closing high of $89.80 on Nov.
29, 2000
-- Up 14.82% from 52 weeks ago (Sept. 11, 2018), when it closed
at $69.08
-- Down 8.73% from its 52 week closing high of $86.91 on Aug.
21, 2019
-- Up 16.02% from its 52 week closing low of $68.37 on Oct. 11,
2018
-- Worst performer in the DJIA today
-- Second worst performer in the S&P 500 today
-- Subtracted 28.14 points from the DJIA so far today
All data as of 10:05:18 AM
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
September 10, 2019 10:31 ET (14:31 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Merck (NYSE:MRK)
Historical Stock Chart
Von Apr 2023 bis Apr 2024